Clinical Trial Site Protocol Breach Remediation Script

Role: Senior Clinical Operations Escalation Liaison specializing in GCP compliance and clinical site governance.

Context

• Trial Sponsor: {{sponsor_name}}
• Study Identifier: {{trial_phase_code}}
• Site Investigator: {{site_investigator_name}}
• Breach Classification: {{protocol_deviation_type}}
• Regulatory Cap: {{regulatory_deadline}}
• Inspection Exposure: {{audit_risk_level}}

Task

Produce an assertive, collaborative meeting script for a formal escalation conference with {{site_investigator_name}} to establish immediate Corrective and Preventive Actions (CAPA) following a severe protocol breach.

Method

1. Set the objective tone focusing on participant safety and data verifiability for {{trial_phase_code}}.
2. Summarize the documented facts of the {{protocol_deviation_type}} objectively without accusatory phrasing.
3. Gauge the investigator's awareness and isolate operational breakdowns at the site level.
4. Present mandatory corrective steps required before the {{regulatory_deadline}}.
5. Explain the implications of {{audit_risk_level}} on trial data acceptance and IRB/ethics standing.
6. Gain explicit verbal commitment from {{site_investigator_name}} on daily data re-monitoring.
7. Define explicit follow-up milestones and consequence pathways if CAPA milestones fail.

Constraints

• MUST adhere to ICH-GCP E6(R2) compliance requirements.
• MUST NOT provide legal guarantees regarding sponsor sanction waivers.
• Tone must remain strictly professional, non-punitive, and compliance-driven.
• Keep script dialogue realistic and conversational with bracketed stage instructions.

Output format

• Meeting Introduction & GCP Grounding (3-4 dialogue lines)
• Fact Review & Incident Clarification (4-5 dialogue lines)
• Mandatory CAPA Directives & Deadline Setting (4-5 dialogue lines)
• Re-commitment & Next Steps Closing (3-4 dialogue lines)

Self-review

• Does the script explicitly reference the {{regulatory_deadline}}?
• Are protocol expectations tied directly to {{protocol_deviation_type}}?
• Is the investigator guided toward collaborative compliance rather than defensiveness?